Bayerische Motoren Werke Aktiengesellschaft

  • WKN: 519000
  • ISIN: DE0005190003
  • Land: Germany

Nachricht vom 19.04.2021 | 18:52

Bayerische Motoren Werke Aktiengesellschaft: Preliminary Key Financial Performance Figures of BMW AG for the first quarter 2021 exceed market expectations

Bayerische Motoren Werke Aktiengesellschaft / Key word(s): Quarterly / Interim Statement/Preliminary Results
Bayerische Motoren Werke Aktiengesellschaft: Preliminary Key Financial Performance Figures of BMW AG for the first quarter 2021 exceed market expectations

19-Apr-2021 / 18:52 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


BMW AG reports sales growth in all significant regions of the world, in particular in China, and in all brands in the first quarter of 2021. In addition, positive price and mix effects, as well as high demand for pre-owned cars, also lead to key financial performance figures of BMW AG which exceed market expectations in a positive current environment.

Based on preliminary figures for the first quarter 2021, Automotive segment EBIT is €2,236 million (Q1 2020: €229 million), Financial Services segment EBT is €787 million (Q1 2020: €484 million) and Group EBT is €3,757 million (Q1 2020: €798 million). The Automotive segment EBIT margin is 9.8% (Q1 2020: 1.3%).

The positive operating performance and the continued focus on working capital management lead to a free cash flow of €2,522 million (Q1 2020: -2,218 million) in the Automotive segment also exceeding market expectations.

The definition of the above-mentioned financial indicators is provided on pages 327 and 328 of the BMW Group Report 2020. Further details will be published in the Quarterly Statement for the period to 31 March 2021 on 7 May 2021.


Contact:
Veronika Rösler
Head of Investor Relations
Tel.: +49-89-382-25387

19-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021